Verwandte Artikel zu Modern Dose-Finding Designs for Cancer Phase I Trials:...

Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents (JSS Research Series in Statistics) - Softcover

 
9784431555728: Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents (JSS Research Series in Statistics)

Inhaltsangabe

THIS BOOK DEALS WITH ADVANCED METHODS FOR ADAPTIVE PHASE I DOSE-FINDING CLINICAL TRIALS FOR COMBINATION OF TWO AGENTS AND MOLECULARLY TARGETED AGENTS (MTAS) IN ONCOLOGY. IT PROVIDES NOT ONLY METHODOLOGICAL ASPECTS OF THE DOSE-FINDING METHODS, BUT ALSO SOFTWARE IMPLEMENTATIONS AND PRACTICAL CONSIDERATIONS IN APPLYING THESE COMPLEX METHODS TO REAL CANCER CLINICAL TRIALS. THUS, THE BOOK AIMS TO FURNISH RESEARCHERS IN BIOSTATISTICS AND STATISTICAL SCIENCE WITH A GOOD SUMMARY OF RECENT DEVELOPMENTS OF ADAPTIVE DOSE-FINDING METHODS AS WELL AS PROVIDING PRACTITIONERS IN BIOSTATISTICS AND CLINICAL INVESTIGATORS WITH ADVANCED MATERIALS FOR DESIGNING, CONDUCTING, MONITORING, AND ANALYZING ADAPTIVE DOSE-FINDING TRIALS. THE TOPICS IN THE BOOK ARE MAINLY RELATED TO CANCER CLINICAL TRIALS, BUT MANY OF THOSE TOPICS ARE POTENTIALLY APPLICABLE OR CAN BE EXTENDED TO TRIALS FOR OTHER DISEASES.&NBSP;THE FOCUS IS MAINLY ON MODEL-BASED DOSE-FINDING METHODS FOR TWO KINDS OF PHASE I TRIALS. ONE IS CLINICAL TRIALS WITH COMBINATIONS OF TWO AGENTS. DEVELOPMENT OF DOSE-FINDING METHODS FOR TWO-AGENT COMBINATION TRIALS REQUIRES REASONABLE MODELS THAT CAN ADEQUATELY CAPTURE JOINT TOXICITY PROBABILITIES FOR TWO AGENTS, TAKING INTO CONSIDERATION POSSIBLE INTERACTIONS OF THE TWO AGENTS ON TOXICITY PROBABILITY SUCH AS SYNERGISTIC OR ANTAGONISTIC EFFECTS. ANOTHER IS CLINICAL TRIALS FOR EVALUATING BOTH EFFICACY AND TOXICITY OUTCOMES IN SINGLE- AND TWO-AGENT COMBINATION TRIALS. THESE METHODS ARE OFTEN APPLIED TO THE PHASE I TRIALS INCLUDING MTAS BECAUSE THE TOXICITY AND EFFICACY FOR A MTA DOES NOT MONOTONICALLY INCREASE WITH DOSE, BUT THE EFFICACY OFTEN INCREASES INITIALLY WITH THE DOSE AND THEN PLATEAUS. SUCCESSFUL SOFTWARE IMPLEMENTATIONS FOR SEVERAL DOSE-FINDING METHODS ARE INTRODUCED IN THE BOOK, AND THEIR OPERATING CHARACTERISTICS IN PRACTICE ARE DISCUSSED. RECENT ADVANCE OF THE ADAPTIVE DOSE-FINDING METHODS IN DRUG DEVELOPMENTS ARE ALSO PROVIDED.<P></P>

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.

Reseña del editor

This book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considerations in applying these complex methods to real cancer clinical trials. Thus, the book aims to furnish researchers in biostatistics and statistical science with a good summary of recent developments of adaptive dose-finding methods as well as providing practitioners in biostatistics and clinical investigators with advanced materials for designing, conducting, monitoring, and analyzing adaptive dose-finding trials. The topics in the book are mainly related to cancer clinical trials, but many of those topics are potentially applicable or can be extended to trials for other diseases. The focus is mainly on model-based dose-finding methods for two kinds of phase I trials. One is clinical trials with combinations of two agents. Development of dose-finding methods for two-agent combination trials requires reasonable models that can adequately capture joint toxicity probabilities for two agents, taking into consideration possible interactions of the two agents on toxicity probability such as synergistic or antagonistic effects. Another is clinical trials for evaluating both efficacy and toxicity outcomes in single- and two-agent combination trials. These methods are often applied to the phase I trials including MTAs because the toxicity and efficacy for a MTA does not monotonically increase with dose, but the efficacy often increases initially with the dose and then plateaus. Successful software implementations for several dose-finding methods are introduced in the book, and their operating characteristics in practice are discussed. Recent advance of the adaptive dose-finding methods in drug developments are also provided.

Biografía del autor

- Akihiro Hirakawa, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo
- Takashi Daimon, Division of Biostatistics, Hyogo College of Medicine
- Hiroyuki Satom, Biostatistics Group, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency
- Shigeyuki Matsui, Department of Biostatistics, Nagoya University Graduate School of Medicine

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

  • VerlagSpringer
  • Erscheinungsdatum2018
  • ISBN 10 4431555722
  • ISBN 13 9784431555728
  • EinbandTapa blanda
  • SpracheEnglisch
  • Anzahl der Seiten104

Gebraucht kaufen

Zustand: Befriedigend
Ship within 24hrs. Satisfaction...
Diesen Artikel anzeigen

Gratis für den Versand innerhalb von/der USA

Versandziele, Kosten & Dauer

EUR 28,91 für den Versand von Deutschland nach USA

Versandziele, Kosten & Dauer

Weitere beliebte Ausgaben desselben Titels

9784431555742: Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents

Vorgestellte Ausgabe

ISBN 10:  4431555749 ISBN 13:  9784431555742
Verlag: Springer, 2018
Softcover

Suchergebnisse für Modern Dose-Finding Designs for Cancer Phase I Trials:...

Beispielbild für diese ISBN

Hirakawa, Akihiro, Sato, Hiroyuki, Daimon, Takashi, Matsui, Shigeyuki
ISBN 10: 4431555722 ISBN 13: 9784431555728
Gebraucht Paperback

Anbieter: BooksRun, Philadelphia, PA, USA

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Paperback. Zustand: Good. 1st ed. 2018. Ship within 24hrs. Satisfaction 100% guaranteed. APO/FPO addresses supported. Artikel-Nr. 4431555722-11-1

Verkäufer kontaktieren

Gebraucht kaufen

EUR 54,85
Währung umrechnen
Versand: Gratis
Innerhalb der USA
Versandziele, Kosten & Dauer

Anzahl: 1 verfügbar

In den Warenkorb

Foto des Verkäufers

Akihiro Hirakawa
Verlag: Springer Japan, 2018
ISBN 10: 4431555722 ISBN 13: 9784431555728
Neu Taschenbuch

Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considerations in applying these complex methods to real cancer clinical trials. Thus, the book aims to furnish researchers in biostatistics and statistical science with a good summary of recent developments of adaptive dose-finding methods as well as providing practitioners in biostatistics and clinical investigators with advanced materials for designing, conducting, monitoring, and analyzing adaptive dose-finding trials. The topics in the book are mainly related to cancer clinical trials, but many of those topics are potentially applicable or can be extended to trials for other diseases.The focus is mainly on model-based dose-finding methods for two kinds of phase I trials. One is clinical trials with combinations of two agents. Development of dose-finding methods for two-agent combination trials requires reasonable models that can adequately capture joint toxicity probabilities for two agents, taking into consideration possible interactions of the two agents on toxicity probability such as synergistic or antagonistic effects. Another is clinical trials for evaluating both efficacy and toxicity outcomes in single- and two-agent combination trials. These methods are often applied to the phase I trials including MTAs because the toxicity and efficacy for a MTA does not monotonically increase with dose, but the efficacy often increases initially with the dose and then plateaus. Successful software implementations for several dose-finding methods are introduced in the book, and their operating characteristics in practice are discussed. Recent advance of the adaptive dose-finding methods in drug developments are also provided. Artikel-Nr. 9784431555728

Verkäufer kontaktieren

Neu kaufen

EUR 67,57
Währung umrechnen
Versand: EUR 28,91
Von Deutschland nach USA
Versandziele, Kosten & Dauer

Anzahl: 2 verfügbar

In den Warenkorb